Results

The results of the present study were statistically analyzed, summarized and presented in 23 tables and 22 figures.

This study included 30 patients with psoriasis and 20 healthy individuals of matched age and sex serving as control group.

Control group:

This group included 15 males (75%) and 5 females (25%) (Table 1 and figure 7). Their ages ranged from 21 - 45 years with (mean ± SD "standard deviation": 32.200 ±7.925)(Table 2 and Fig. 8).

Patient group

This group included 30 psoriasis patients, 22 males (73.3%) and 8 females (26.7%) (Table 1 and figure 7).Their ages ranged from 20-50 years (mean ± SD: 36.300 ± 8.035).(Table 2 and Fig. 8).

Comparison between patients and control group regarding gender and age revealed no significant difference (Table 1,2 and Fig 7,8).

Table (1):Gender of studied psoriasis patients and control group.

Gender		Patients	Control	Total
Female	N	8	5	13
	%	26.67	25.00	26.00
Male	N	22	15	37
	%	73.33	75.00	74.00
Total	N	30	20	50
	%	100.0	100.0	100.0
Chi-square	X^2	0.00		
	P-value	1.00		



Fig.(7) Gender of studied psoriasis patients and control group.

Table(2):Age of the studied psoriasis patients and control group.

Groups	Age (years)		T-test	
	Range	Mean ± SD	t	P-value
Patients	20.00 - 50.00	36.300 ± 8.035	1.777	0.082
Controls	21.00 - 45.00	32.200 ± 7.925		



Fig.(8):Age of the studied psoriasis patients and control group.

Table (3): Body mass index of the studied psoriasis patients and control group.

Groups	BMI (kg/m2)		T-test	
	Range	Mean ± SD	t	P-value
Patients	21.10 - 30.00	24.083 ± 1.884	1.241	0.220
Controls	21.30 - 29.90	24.900 ± 2.779		

Table (3) and fig. (9) showed that BMI of patients' group ranged from 21-30 (mean± SD : 24.083±1.884),while in control group , BMI ranged from 21.30 - 29.90 (mean ± SD 24.900 -2.779). comparison between the studied patients and control group as regard BMI revealed no significant difference where P value o.220 .



Fig.(9): Body mass index of the studied psoriasis patients and control group.

Table (4): Systolic blood pressure of the studied psoriasis patients and control group.

Groups	SBP		T-test	
	Range	Mean ± SD	t	P-value
Patients	100.00 - 130.00	119.500 ± 8.939	0.206	0.838
Controls	110.00 - 130.00	119.000 ± 7.539		

Table (4) and fig.(10) showed that the systolic blood pressure (SBP) among the studied patients ranged from 100-130mmHg (mean ± SD:119.500 ± 8.939), while in the control group it ranged from 110-130mmHg (mean ±SD:119 ±7.539). Comparison between the studied patients and control group as regard SBP revealed no significant difference where P value 0.838.



Fig.(10): Systolic blood pressure of the studied psoriasis patients and control group.

Table(5):Diastolic blood pressure of the studied psoriasis patients and control group.

Groups	DBP		T-test	
	Range	Mean ± SD	t	P-value
Patients	60.00 - 95.00	76.500 ± 9.926	0.617	0.540
Controls	60.00 - 90.00	74.750 ± 9.662		

Table (5) and fig.(11) showed that the diastolic blood pressure (DBP) among the studied patients ranged from 60-95 mmHg (mean ± SD:76.500 ± 9.926),while in the control group ranged from 60-90 mmHg (mean ±SD:74.750±9.662.Comparison between the studied patients and control group as regard DBP revealed no significant difference where P value 0.540.



Fig.(11):):Diastolic blood pressure of the studied psoriasis patients and control group.

Table(6):clinical variants of psoriasis among studied psoriasis patients.

Clinical variant Of psoriasis	N	%
Flexural psoriasis	3	10.00
Guttate psoriasis	3	10.00
Scalp psoriasis	1	3.33
Palmoplanter psoriasis	3	10.00
Plaque psoriasis	20	66.67
Total	30	100.00

Table (6) and fig.(12) showed the clinical variants of psoriasis among the studied psoriasis patients where the flexural t ype was 10 % (N= 3), guttate psoriasis was 10 % (N=3), scalp psoriasis was 3.33 (N=1), palmoplanter type was 10%(N =3) and the plaque type was 66.67% (N=20).



Fig.(12):clinical variants of psoriasis among the studied psoriasis patients.

Table(7):Psoriasis duration and PASI score among the studied psoriasis patients.

	Range	Mean ± SD
Psoriasis duration (years)	1.00 - 15.00	8.100 ± 4.063
PASI score	3.40 - 49.00	16.300 ± 11.880

Table (7) showed that the duration of psoriasis in the studied patients group ranged from 1-15 years (mean± SD:8.100±4.063),and their PASI score ranged from 3.40-49 (mean± SD=16.300±11.880).

Labolatory results:

Table(8):serum CRP level in the studied psoriasis patients and control group.

Groups	CRP mg/dl		T-test	
	Range	Mean ± SD	t	P-value
Patients	5.10 - 9.20	7.043 ± 1.205	10.191	<0.001*
Controls	2.90 - 5.30	4.075 ± 0.595		

Table (8) and fig.(13) showed that serum level of CRP in the studied psoriasis patients ranged from 5.10-9.20 mg/dl (mean±SD:7.043±1.205) , while in the control group it ranged from 2.90-5.30 mg/dl (mean±SD:4.075±o.595).There was highly significant increase in serum CRP in the patients' group when compared with the control group where P value <0.001.



Fig.(13):serum CRP level in the studied psoriasis patients and control group.

Table(9):serum Hcy level in the studied psoriasis patients and control group.

Groups	Hcy (µmol/l)		T-test	
	Range	Mean ± SD	t	P-value
Patients	12.80 - 45.10	19.653 ± 8.087	4.713	<0.001*
Controls	6.30 - 14.20	10.980 ± 1.692		

Table (9) and fig.(14) showed that serum level of Hcy in the studied psoriatic patients ranged from 12.8-45.10µmol/L (mean±SD:19.653±8.087), while in the control group it ranged from 6.30-14.20 µmol/L (mean±SD:10.980±1.692). There was highly significant increase in serum Hcy in the patients' group when compared with the control group where P value <0.001.



Fig.(14):Serum Hcy level in studied psoriasis patients and control group.

Table(10):serum folic acid level in studied psoriasis patients and control group.

Groups	Folic acid ng/ml		T-test	
	Range	Mean ± SD	t	P-value
Patients	3.30 - 7.60	5.173 ± 1.132	-18.981	<0.001*
Controls	10.00 - 14.80	11.460 ± 1.171		

Table (10) and fig.(15) showed that serum level of folic acid in the studied psoriatic patients ranged from 3.30-7.60 ng/ml (mean±SD:5.173±1.132), while in the control group it ranged from 10-14.80 ng/ml (mean±SD:11.460±1.171). There was highly significant decrease in serum folic acid in the patients' group when compared with the control group, where P value <0.001.



Fig.(15):serum folic acid level in studied psoriasis patients and control group.

Table(11): serum VB12 level in the studied psoriasis patients and control group.

Groups	VB12(pg/ml)		T-test	
	Range	Mean ± SD	t	P-value
Patients	170.10 - 235.50	199.413 ± 15.950	-14.524	<0.001*
Controls	233.40 - 295.60	268.305 ± 17.141		

Table (11) and fig. (16) showed that serum level of VB12 in the studied psoriasis patients ranged from 170.10-235.50 pg/ml (mean±SD:199.413±15.950), while in the control group it ranged from 233.40-295.60 pg/ml (mean±SD:268.305±17.141). There was highly significant decrease in serum VB12 in the patients' group when compared with the control group, where P value <0.001.



Fig.(16):serum VB12level in the studied psoriasis patients and control group.

Table (12)Level of PT in the studied psoriasis patients and control group.

Groups	PT (seconds)		T-test	
	Range	Mean ± SD	t	P-value
Patients	8.70 - 14.60	10.957 ± 1.430	-6.328	<0.001*
Controls	11.50 - 14.30	13.140 ± 0.698		

Table (12) and fig.(17)showed that the level of PT in the studied psoriatic patients ranged from 8.70-14.60 seconds (mean±SD:10.957±1.430) ,while in the control group it ranged from 11.50-14.30 seconds (mean±SD:13.140±0.698). There was highly significant decrease in PT in the patients' group when compared with the control group, where P value <0.001.



Fig.(17)Level of PT in the studied psoriasis patients and control group.

Table(13):Level of PTT in the studied psoriasis patients and control group.

Groups	PTT (seconds)		T-test	
	Range	Mean ± SD	t	P-value
Patients	23.00 - 45.30	33.460 ± 3.827	-0.476	0.636
Controls	21.90 - 41.10	34.030 ± 4.589		

Table (13) and fig.(18) showed that the level of PTT in the studied psoriasis patients ranged from 23-45.30 seconds (mean±SD:33.460±3.827), while in the control group it ranged from 21.90 - 41.10 seconds (mean±SD:34.030±4.589). The difference between both groups as regard PTT was non significant ,where P value 0.636.



Fig.(18)Level of PTT in the studied psoriasis patients and control group.

Table(14): Level of AT-III in the studied psoriasis patients and control group.

Groups	AT-III mg/dl		T-test	
	Range	Mean ± SD	t	P-value
Patients	16.00 - 27.00	20.530 ± 3.314	7.440	<0.001*
Controls	22.00 - 44.00	31.710 ± 7.190		

Table (14) and fig.(19) showed that the level of AT-III in the studied psoriasis patients ranged from 16-27 mg/dl (mean±SD:20.530±3.314) ,while in the control group ranged from 22-44 (mean±SD:31.710±7.190). There was highly significant decrease in serum AT-III level in the patients' group when compared with the control group, where P value <0.001.



Fig.(19): Level of AT-III in the studied psoriasis patients and control group.

Table(15):Correlation between serumCRP level and psoriasis severity(PASI) in the studied psoriasis patients.

	CRP(mg/dl)	
	r	**P-value**
Severity(PASI)	0.791	<0.001*

Table (15) and fig.(20) showed that there was a significant positive correlation between serum CRP level and psoriasis severity (PASI score) where $p < 0.001$ and $r = 0.791$.



Fig.(20):Correlation between serumCRP level and psoriasis severity(PASI) in the studied psoriasis patients.

Table(16):Correlation between serum Hcy level and severity of psoriasis in the studied patients

	Hcy(µmol/L)	
	r	**P-value**
Severity(PASI score)	0.808	<0.001*

Table (16) and fig.(21) showed that there was a significant positive correlation between serum Hcy level and psoriasis severity (PASI score) where $p < 0.001$ and $r = 0.808$.



Fig.(21):Correlation between serum Hcy level and severity of psoriasis in the studied patients.

Table(17):Correlation between PT level and severity of psoriasis in the studied patients.

	PASI score	
	r	P-value
PT (seconds)	-0.767	<0.001*

Table (17) and fig.(22) showed that there was a significant negative correlation between PT level and psoriasis severity (PASI score) where $p < 0.001$ and $r = -0.767$.



Fig.(22):Correlation between PT level and severity of psoriasis in the studied patients.

Table(18):Correlation between PTT level and severity of psoriasis (PASI) in the studied patients.

	PASI score	
	r	P-value
PTT (seconds)	-0.651	<0.001*

Table (18) and fig.(23) showed that there was a significant negative correlation between PTT level and psoriasis severity (PASI score) where $p < 0.001$ and $r = -0.651$.



Fig.(23):Correlation between PTT level and severity of psoriasis in the studied patients.

Table(19):Correlation between AT-III level and psoriasis severity(PASI) in the studied psoriasis patients.

	Severity(PASI score)	
	r	**P-value**
AT-III (mg/dl)	-0.810	<0.001*

Table (19) and fig.(24) showed that there was a significant negative correlation between AT III level and psoriasis severity (PASI score) where $p < 0.001$ and $r = -0.810$.



Fig.(24):Correlation between ATIII level and psoriasis severity(PASI) in the studied psoriasis patients.

Table(20):Correlation between serum Hcy level and age of studied psoriasis patients.

	Hcy (µmol/l)	
	r	**P-value**
Age (years)	0.763	<0.001*

Table (20) and fig.(25) showed that there was a significant positive correlation between serum Hcy level and the age of the studied psoriasis patients , where $p < 0.001$ and $r = 0.763$.



Fig.(25):correlation between serum Hcy level and age of the studied psoriasis patients.

Table (21):Correlation between serum Hcy level and duration of psoriasis in the studied patients.

	Hcy(µmol/L)	
	r	**P-value**
Psoriasis duration(years)	0.888	<0.001*

Table (21) and fig.(26) showed that there was a significant positive correlation between serum Hcy level and the duration of psoriasis in the studied psoriasis patients , where $p < 0.001$ and r=0.888.



Fig.(26):Correlation between serum Hcy level and duration of psoriasis in the studied patients.

Table(22):Correlation between serum Hcy level and folic acid level in the studied psoriasis patients.

	Hcy(µmol/L)	
	r	**P-value**
Folic acid(ng/ml)	-0.737	<0.001*

Table (22) and fig.(27) showed that there was a significant negative correlation between serum Hcy level and and serum folic acid level in the studied psoriasis patients , where $p < 0.001$ and $r = -0.737$.



Fig.(27):Correlation between serum Hcy level and folic acid level in the studied psoriasis patients.

Table(23):Correlation between serum Hcy level and VB12 level in the studied psoriasis patients.

	Hcy(µmol/L)	
	r	**P-value**
VB12(pg/ml)	-0.758	<0.001*

Table (23) and fig.(28) showed that there was a significant negative correlation between serum Hcy level and and serum VB12 level in the studied psoriasis patients , where $p < 0.001$ and $r = - 0.758$.



Fig.(28):Correlation between serum Hcy level and VB12 level in the studied psoriasis patients.